Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma

Objectives To investigate the efficacy, safety, and cost of a pomalidomide‐dexamethasone regimen in patients with relapsed and refractory multiple myeloma (RRMM). Methods All patients (n = 63) treated with pomalidomide‐dexamethasone for RRMM in our university hospital between August 2013 and October 2015 were included. Results Pomalidomide was discontinued early due to progression (before the 4th cycle) in 17 (27%) patients. No case was discontinued for intolerance. The only independent factor that predicted early pomalidomide discontinuation was time from diagnosis to pomalidomide initiation